These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 33315067)

  • 21. Recent updates on drug resistance in Mycobacterium tuberculosis.
    Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T
    J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects.
    Yew WW
    Kekkaku; 2011 Jan; 86(1):9-16. PubMed ID: 21401001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tuberculosis and its Treatment: An Overview.
    Bansal R; Sharma D; Singh R
    Mini Rev Med Chem; 2018; 18(1):58-71. PubMed ID: 27553018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repurposing Immunomodulatory Drugs to Combat Tuberculosis.
    Fatima S; Bhaskar A; Dwivedi VP
    Front Immunol; 2021; 12():645485. PubMed ID: 33927718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
    Pawar UM; Kundnani V; Agashe V; Nene A; Nene A
    Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitubercular drugs: possible role of natural products acting as antituberculosis medication in overcoming drug resistance and drug-induced hepatotoxicity.
    Rana HK; Singh AK; Kumar R; Pandey AK
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Mar; 397(3):1251-1273. PubMed ID: 37665346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nano-Drug Delivery Systems: Possible End to the Rising Threats of Tuberculosis.
    Sheikh BA; Bhat BA; Alshehri B; Mir RA; Mir WR; Parry ZA; Mir MA
    J Biomed Nanotechnol; 2021 Dec; 17(12):2298-2318. PubMed ID: 34974855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An updated patent review on drugs for the treatment of tuberculosis (2018-present).
    Ahmed S; Nandi S; Saxena AK
    Expert Opin Ther Pat; 2022 Mar; 32(3):243-260. PubMed ID: 34846976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Of tuberculosis and non-tuberculous mycobacterial infections - a comparative analysis of epidemiology, diagnosis and treatment.
    Gopalaswamy R; Shanmugam S; Mondal R; Subbian S
    J Biomed Sci; 2020 Jun; 27(1):74. PubMed ID: 32552732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Updates in the Treatment of Active and Latent Tuberculosis.
    Haas MK; Belknap RW
    Semin Respir Crit Care Med; 2018 Jun; 39(3):297-309. PubMed ID: 30071545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tuberculosis clinical trial update and the current anti-tuberculosis drug portfolio.
    Palomino JC; Martin A
    Curr Med Chem; 2013; 20(30):3785-96. PubMed ID: 23862617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multi-Drug Resistant and Extensively-Drug Resistant Tuberculosis.
    Shah I; Poojari V; Meshram H
    Indian J Pediatr; 2020 Oct; 87(10):833-839. PubMed ID: 32103425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review of inhalable nanoparticles for the pulmonary delivery of anti-tuberculosis drugs.
    Ramachandran S; Prakash P; Mohtar N; Kumar KS; Parumasivam T
    Pharm Dev Technol; 2023 Dec; 28(10):978-991. PubMed ID: 37937865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Old antibiotics for emerging multidrug-resistant/extensively drug-resistant tuberculosis (MDR/XDR-TB).
    Brouqui P; Quenard F; Drancourt M
    Int J Antimicrob Agents; 2017 May; 49(5):554-557. PubMed ID: 28336312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.
    Young EF; Perkowski E; Malik S; Hayden JD; Durham PG; Zhong L; Welch JT; Braunstein MS; Hickey AJ
    Pharm Res; 2016 Oct; 33(10):2495-505. PubMed ID: 27351427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of multi-drug resistant tuberculosis: practitioner's view point.
    Prasad R
    Indian J Tuberc; 2007 Jan; 54(1):3-11. PubMed ID: 17455417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Biologics and mycobacterial diseases].
    Tsuyuguchi K; Matsumoto T
    Kekkaku; 2013 Mar; 88(3):337-53. PubMed ID: 23672175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.